Cooperative Agreement UG3CA301294
Award Date 8/11/25
Completion Date 5/31/27
Dollars Obligated $728K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
New York, USA
Similar Awards
- This $2,864,671 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Regents of the University of Michigan is focused on developing a novel strategy to enzymatically inhibit colibactin, a procarcinogenic metabolite from enteric bacteria associated with colorectal cancer (CRC). The objectives are to: (1) create engineered microbes that can deliver the colibactin inactivation protein ClbS to safely and effectively neutralize colibactin in the gut,...
- This $627,422 Project Grant award from the National Cancer Institute under the Cancer Treatment Research (CFDA 93.395) program supports research by the Regents of the University of Michigan to engineer commensal bacteria that can neutralize the colibactin genotoxin produced by certain gut bacteria associated with increased colorectal cancer risk. The key products and services to be delivered under this 5-year grant include: 1) Further optimization of the surface display of the anti-toxin...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $392,827 to Endure Biotherapeutics, Inc. to develop a novel engineered native bacteria (ENB) therapy for the treatment of familial adenomatous polyposis (FAP), a genetic condition that leads to colorectal cancer. The project aims to engineer gut bacteria to express therapeutic gene products that can effectively colonize the gut and suppress the progression of colon adenomas, thereby...
- This federal Project Grant award of $606,839.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to identify gut microbiota that actively deplete intestinal amino acids and evaluate how they affect the tumor microenvironment and cancer progression. The primary awardee is Weill Medical College of Cornell University, a leading academic medical institution with expertise in biomedical research and translational science. The project aims to...
- The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $670,534 Project Grant to Northwestern University to develop an optical hyperspectral nanoscale chromatin analysis technology for colorectal cancer risk stratification. The goal is to create a screening test to identify patients who harbor advanced adenomas and should undergo colonoscopy, with a target of 99.5% negative predictive value, 95% sensitivity, and 80% specificity for advanced adenomas....
- This federal Project Grant award of $400,890.00 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to profile patient-specific tumor-microbiome interactions and conduct quantitative molecular analyses to elucidate microbiome-mediated modulation of immune checkpoint molecules in mismatch repair-proficient, microsatellite-stable colorectal tumors. The goal is to provide a strategic roadmap and personalized workflow to enhance immunotherapeutic effects on non-responsive...
- This Project Grant award of $600,499.00 from the National Cancer Institute, under the Cancer Biology Research program (CFDA 93.396), supports research conducted by The Trustees of Columbia University in the City of New York (Health Sciences Division) to investigate the role of the Fusobacterium nucleatum (FN) bacterium and the Annexin A1 (ANXA1) protein as potential biomarkers in colorectal cancer oncogenesis. The key objectives of this 5-year project are to: (I) mechanistically investigate...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support the development of a "Spatial Profiling-Based Immune Hub Perturbation Platform" to improve immunotherapy for colorectal cancer. The $710,361 award to J. David Gladstone Institutes will fund research to create a novel experimental framework to systematically test and prioritize candidate genes and therapies based on their ability to induce effective anti-tumor immune hubs -...
- This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) totaling $638,120 provides funding to The Trustees of Columbia University in the City of New York to conduct research aimed at improving the therapeutic efficacy and safety of microbial neoantigen vaccines for cancer treatment. The key objectives are to: 1) explore how bacterial localization within tumors affects immune responses and therapeutic outcomes, 2) investigate how bacterial...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Stanford University to investigate how the human gut microbiome can be modulated to enhance immune responses against cancer, with a focus on improving the efficacy of cancer immunotherapy treatments. The $179,988 award, which runs from January 1, 2025 to December 31, 2026, aims to identify bacterial genes and functions that can boost the body's immune response to immune...